Stereotaxis Revenue Nearly Doubles, Net Loss Narrows Amid Product Launches

TL;DR

**STXS is finally showing strong revenue traction with new products, but cash burn remains a concern; watch for FDA approvals to fuel the next leg up.**

AI Summary

Stereotaxis, Inc. (STXS) reported a significant increase in total revenue for the three months ended June 30, 2025, reaching $8.798 million, up from $4.502 million in the prior year, a 95.4% increase. This was primarily driven by a surge in Systems revenue to $3.038 million from $0.240 million, and Disposables, service and accessories revenue increasing to $5.760 million from $4.262 million. Despite this revenue growth, the company posted a net loss of $3.826 million for the quarter, an improvement from a net loss of $5.833 million in the same period last year. For the six months ended June 30, 2025, total revenue was $16.270 million, up from $11.382 million, while net loss was $9.649 million, an improvement from $10.340 million. Cash and cash equivalents decreased from $12.217 million at December 31, 2024, to $6.967 million at June 30, 2025. Key business changes include the acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024, enhancing in-house catheter development, and the attainment of CE Mark for the GenesisX RMN System in Q3 2024, with FDA 510(k) clearance pending. The Stereotaxis MAGiC catheter obtained CE marking in Q1 2025, and the MAGiC Sweep catheter received FDA 510(k) clearance in July 2025, indicating a strong product development pipeline.

Why It Matters

Stereotaxis's substantial revenue growth, particularly in system sales, signals increasing adoption of its robotic magnetic navigation technology, which could be a game-changer for investors looking at the medical device sector. For patients and healthcare providers, the new GenesisX RMN System and MAGiC catheters promise more precise, safer, and efficient cardiac ablation procedures, potentially improving outcomes and reducing x-ray exposure. The company's strategic acquisition of APT and ongoing regulatory approvals for new devices like the MAGiC Sweep catheter position it to gain market share in the competitive electrophysiology space, challenging traditional manual catheterization methods. This innovation could drive long-term value and solidify its niche in robotic interventional medicine.

Risk Assessment

Risk Level: medium — While revenue growth is strong, Stereotaxis reported a net loss of $9.649 million for the six months ended June 30, 2025, and cash and cash equivalents declined by $5.250 million to $6.967 million from December 31, 2024. The company's continued reliance on regulatory approvals for new products like the GenesisX RMN System in the U.S. and the MAGiC catheter in other geographies introduces uncertainty and potential delays, impacting future revenue streams.

Analyst Insight

Investors should monitor STXS's cash burn rate and progress on FDA approvals for its GenesisX RMN System and MAGiC catheter. A successful U.S. launch of these products could significantly improve financial performance and reduce risk, making it a potential buy for growth-oriented investors willing to tolerate some near-term volatility.

Financial Highlights

debt To Equity

N/A

revenue

$8.798M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$3.826M

eps

N/A

gross Margin

N/A

cash Position

$6.967M

revenue Growth

+95.4%

Revenue Breakdown

Key Numbers

• $8.798M — Total Revenue (Q2 2025) (Increased 95.4% from $4.502M in Q2 2024)
• $3.038M — Systems Revenue (Q2 2025) (Increased from $0.240M in Q2 2024, indicating strong system adoption)
• $5.760M — Disposables, Service & Accessories Revenue (Q2 2025) (Increased from $4.262M in Q2 2024, showing growth in recurring revenue)
• $(3.826M) — Net Loss (Q2 2025) (Improved from $(5.833M) in Q2 2024)
• $16.270M — Total Revenue (Six Months Ended June 30, 2025) (Increased from $11.382M in the prior year period)
• $(9.649M) — Net Loss (Six Months Ended June 30, 2025) (Improved from $(10.340M) in the prior year period)
• $6.967M — Cash and Cash Equivalents (June 30, 2025) (Decreased from $12.217M at December 31, 2024)
• 90,653,769 — Outstanding Common Shares (July 31, 2025) (Reflects share count after recent activities)

Key Players & Entities

• Stereotaxis, Inc. (company) — Registrant
• Access Point Technologies EP, Inc. (company) — Acquired company
• FDA (regulator) — U.S. Food and Drug Administration
• National Medical Products Administration (NMPA) (regulator) — China's regulatory body
• MicroPort (company) — Partner in China
• $8.798 million (dollar_amount) — Total revenue for Q2 2025
• $3.826 million (dollar_amount) — Net loss for Q2 2025
• $6.967 million (dollar_amount) — Cash and cash equivalents at June 30, 2025
• GenesisX RMN System (product) — Latest generation robotic magnetic navigation system
• MAGiC catheter (product) — Robotically navigated magnetic ablation catheter

FAQ

Risk Factors

• Cash Burn and Liquidity Concerns [high — financial]: The company's cash and cash equivalents decreased from $12.217 million at December 31, 2024, to $6.967 million at June 30, 2025. This significant reduction highlights ongoing operational cash burn and raises concerns about future liquidity if revenue growth does not outpace expenses.
• FDA 510(k) Clearance Dependency [medium — regulatory]: The company is awaiting FDA 510(k) clearance for its GenesisX RMN System. Delays or failure to obtain this clearance could significantly impact the commercialization and revenue potential of this key product.
• Integration of Acquired Assets [medium — operational]: The acquisition of Access Point Technologies EP, Inc. (APT) on July 31, 2024, while enhancing in-house catheter development, introduces integration risks. Successful integration is crucial for realizing the strategic benefits and avoiding operational disruptions.
• Competition in Electrophysiology Market [medium — market]: The electrophysiology market is competitive, with established players and ongoing technological advancements. Stereotaxis must continuously innovate and demonstrate the clinical and economic benefits of its systems to maintain and grow market share.

Industry Context

Stereotaxis operates in the highly specialized and competitive electrophysiology (EP) market, which focuses on diagnosing and treating heart rhythm disorders. Key trends include the shift towards minimally invasive procedures, increasing adoption of robotic navigation for enhanced precision and safety, and a strong emphasis on developing advanced catheter technologies. Competitors range from large medical device conglomerates to specialized EP companies, all vying for market share through innovation and clinical evidence.

Regulatory Implications

The company faces significant regulatory hurdles, particularly obtaining FDA 510(k) clearance for new systems like GenesisX and ensuring ongoing compliance with global medical device regulations. Successful navigation of these processes is critical for market access and revenue generation, while delays or rejections can severely impact growth prospects.

What Investors Should Do

1. Monitor cash burn rate closely: Given the decrease in cash reserves, investors should track the company's ability to manage expenses and generate positive cash flow from operations.
2. Track progress on FDA 510(k) clearance for GenesisX: This clearance is a key catalyst for future revenue growth and should be a primary focus for investors.
3. Analyze the growth drivers of recurring revenue: Investors should assess the sustainability of the increase in Disposables, Service & Accessories revenue, as it indicates the health of the installed base and customer retention.
4. Evaluate the impact of the APT acquisition: Monitor the integration progress and its contribution to the company's product development pipeline and overall strategy.

Key Dates

• 2024-07-31: Acquisition of Access Point Technologies EP, Inc. (APT) — Strengthens in-house catheter development capabilities, potentially leading to improved product innovation and control over the supply chain.
• Q3 2024: Attainment of CE Mark for GenesisX RMN System — Allows for commercialization in European markets, indicating regulatory progress and market expansion potential.
• Q1 2025: Stereotaxis MAGiC catheter obtained CE marking — Expands market access for a key disposable product in Europe, contributing to recurring revenue streams.
• 2025-07-XX: MAGiC Sweep catheter received FDA 510(k) clearance — Opens up the significant US market for this new catheter, a crucial step for revenue growth and market penetration.
• 2025-06-30: End of Q2 2025 — Reporting period for the 10-Q, showing significant revenue growth but continued net loss and reduced cash reserves.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a continuing view of the company's financial position during the year. (This document provides the detailed financial and operational information analyzed here.)

FDA 510(k) clearance

A premarket submission made to the FDA to demonstrate that the device is at least as safe and effective, that is, substantially equivalent, to a legally marketed device. (Crucial for launching new medical devices in the United States market, impacting revenue potential.)

CE Mark

A certification that a product has met EU standards for health, safety, and environmental protection, allowing it to be sold within the European Economic Area (EEA). (Essential for market access and sales within European countries.)

Systems Revenue

Revenue generated from the sale or lease of Stereotaxis' robotic navigation systems. (Indicates the company's ability to place its capital equipment, a precursor to recurring revenue.)

Disposables, Service & Accessories Revenue

Recurring revenue generated from the sale of catheters, accessories, and maintenance/support services for the installed base of systems. (Represents a stable and often higher-margin revenue stream, crucial for long-term profitability.)

Year-Over-Year Comparison

Compared to the prior year period, Stereotaxis has demonstrated a remarkable acceleration in revenue growth, with total revenue nearly doubling in Q2 2025 due to a substantial increase in Systems revenue. While the net loss has narrowed, indicating improved operational efficiency relative to revenue, the company's cash position has significantly declined. New risks related to product clearances and integration of recent acquisitions are now more prominent.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share STXS NYSE American LLC

Filing Documents

• form10-q.htm (10-Q) — 1242KB
• ex31-1.htm (EX-31.1) — 13KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001641172-25-023417.txt ( ) — 6595KB
• stxs-20250630.xsd (EX-101.SCH) — 44KB
• stxs-20250630_cal.xml (EX-101.CAL) — 71KB
• stxs-20250630_def.xml (EX-101.DEF) — 205KB
• stxs-20250630_lab.xml (EX-101.LAB) — 379KB
• stxs-20250630_pre.xml (EX-101.PRE) — 309KB
• form10-q_htm.xml (XML) — 1126KB

Financial Statements (unaudited)

Financial Statements (unaudited) 3-7 Consolidated Balance Sheets 3 Consolidated 4 Consolidated 5 -6 Consolidated 7 Notes to Financial Statements 8-22 Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 23-29 Item 3. [Reserved] 29 Item 4. Controls and Procedures 29 Part II Other Information Item 1. Legal Proceedings 30 Item 1A. Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults upon Senior Securities 30 Item 4. [Reserved] 30 Item 5. Other Information 30 Item 6. Exhibits 30

Signatures

Signatures 31 2 ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS STEREOTAXIS, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share amounts) June 30, 2025 December 31, 2024 (Unaudited) Assets Current assets: Cash and cash equivalents $ 6,967 $ 12,217 Restricted cash - current - 219 Accounts receivable, net of allowance of $ 582 at 2025 and 2024 4,393 3,824 Inventories, net 9,608 8,331 Prepaid expenses and other current assets 936 1,848 Total current assets 21,904 26,439 Property and equipment, net 3,284 3,573 Goodwill 3,764 3,764 Intangible assets, net 6,899 7,358 Operating lease right-of-use assets 5,204 5,483 Prepaid and other non-current assets 118 107 Total assets $ 41,173 $ 46,724 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 6,730 $ 5,668 Accrued liabilities 1,731 2,922 Deferred revenue 5,843 6,804 Current contingent consideration 5,839 5,638 Current portion of operating lease liabilities 605 570 Total current liabilities 20,748 21,602 Long-term deferred revenue 1,057 2,064 Long term contingent consideration 6,384 6,126 Operating lease liabilities 5,122 5,436 Other liabilities 1,110 64 Total liabilities 34,421 35,292 Series A - Convertible preferred stock: Convertible preferred stock, Series A, par value $ 0.001 ; 10,000,000 shares authorized; 21,233 and 21,458 shares outstanding at 2025 and 2024, respectively 5,296 5,352 Convertible preferred stock, Series A, par value $0.001; 10,000,000 shares authorized; 21,233 and 21,458 shares outstanding at 2025 and 2024, respectively 5,296 5,352 Stockholders' equity: Common stock, par value $ 0.001 ; 300,000,000 shares authorized, 86,004,864 and 85,326,557 shares issued at 2025 and 2024, respectively 86 85 Common stock, par value $0.001; 300,000,000 shares authorized, 86,004,864 and 85,326,557 shares issued at 2025 and 2024, respectively 86 85 Addi

View Full Filing

View this 10-Q filing on SEC EDGAR